Gillian M Beattie

US Patent:

6413773, Jul 2, 2002

Filed:

May 26, 1999

Appl. No.:

09/320479

Inventors:

Andrezej Ptasznik - Philadelphia PA
Alberti Hayek - La Jolla CA
Gillian M. Beattie - Poway CA

Assignee:

The Regents of the University of California - Oakland CA

International Classification:

C12N 506

US Classification:

435377, 375366

Abstract:

This invention pertains to the discovery that inhibition of phosphatidylinositol 3-kinase (PI3K) in human fetal undifferentiated cells induces morphological and functional endocrine differentiation. This is associated with an increase in mRNA levels of insulin, glucagon, and somatostatin, as well as an increase in the insulin protein content and secretion response to secretagogues. Blockade of PI3K also increases the proportion of pluripotent precursor cells coexpressing multiple hormones and the total number of terminally differentiated cells originating from these precursor cells.

US Patent:

20030202967, Oct 30, 2003

Filed:

Mar 27, 2003

Appl. No.:

10/402194

Inventors:

Fred Levine - Del Mar CA, US
Sijian Wang - Dallas TX, US
Gillian Beattie - Poway CA, US
Alberto Hayek - La Jolla CA, US

International Classification:

A61K048/00
C12N015/867
C12N005/08

US Classification:

424/093210, 435/456000, 435/366000, 435/320100

Abstract:

This invention relates to cell lines, particularly mammalian cell lines, established by transforming the cells with vectors, preferably retroviral vectors, containing two or more oncogenes under the control of one or more inducible promoters and/or genetic elements. Also within the scope of the invention are human cell lines with extended in vitro lifespan, transformed by vectors containing one or more oncogenes under the control of one or more, preferably exogenous, inducible promoters and/or genetic elements. The vectors may additionally contain gene(s) encoding for desired gene product(s). Also disclosed are insulin producing human pancreatic cell lines useful for transplantation into human diabetic patients.

US Patent:

20030228287, Dec 11, 2003

Filed:

Oct 18, 2002

Appl. No.:

10/274529

Inventors:

Gillian Beattie - San Diego CA, US
Alberto Hayek - La Jolla CA, US
Anthony Montgomery - Cardiff CA, US

Assignee:

Regents of the University of California

International Classification:

A61K045/00
C12N005/08

US Classification:

424/093700, 435/366000

Abstract:

The present invention provides a method of culturing cells on a matrix. The present invention includes islet cells cultured in a 3-D configuration in the presence of a fibrin matrix support. Induction of -cell proliferation with HGF/SF is also provided.

US Patent:

20090155218, Jun 18, 2009

Filed:

Mar 9, 2005

Appl. No.:

10/598682

Inventors:

Alberto Hayek - La Jolla CA, US
Gillian Beattie - San Diego CA, US
Ana Lopez - San Diego CA, US

International Classification:

A61K 45/00
C12N 5/08
A61P 35/00

US Classification:

424 937, 435374, 435366

Abstract:

The present invention relates to methods, compositions, and kits for maintenance of the undifferentiated state and/or pluripotency in stem cells, including embryonic stem (ES) cells. It also relates to stem cells that have been maintained in an undifferentiated state. The present invention provides these aspects using culture medium enriched with a TGFβ family member protein, an FGF family member protein, and/or nicotinamide, without using fibroblast feeder layers, conditioned media, or leukemia inhibitory factor.

US Patent:

55873090, Dec 24, 1996

Filed:

Apr 29, 1994

Appl. No.:

8/235394

Inventors:

Jeffrey Rubin - Rockville MD
Alberto Hayek - La Jolla CA
Gillian M. Beattie - Poway CA
Timo P. J. Otonkoski - La Jolla CA

Assignee:

The United States of America as represented by the Department of Health
and Human Services - Washington DC
Whittler Institute for Diabetes and Endocrinology - La Jolla CA

International Classification:

C12N 500
C12N 502

US Classification:

4352402

Abstract:

A method of inducing the proliferation and/or differentiation of human fetal pancreatic cells entails contacting such cells in primary culture with Hepatocyte Growth Factor/Scatter Factor, thereby inducing a proliferation of. beta. -epithelial cells, an increase in the number of. beta. -epithelial cells which form islet-like cell clusters, and an increase in insulin production per cell. The method provides increased numbers of functional islet-like cell clusters for transplantation, for example, into Type 1 diabetic patients. The method can be scaled up so as to provide clinically useful numbers of cells for transplantation.

US Patent:

58743065, Feb 23, 1999

Filed:

Dec 12, 1996

Appl. No.:

8/764467

Inventors:

Gillian M. Beattie - Poway CA
Alberto Hayek - La Jolla CA

Assignee:

The Regents of the University of California - Oakland CA

International Classification:

C12N 508
C12N 506
C12N 1100

US Classification:

435366

Abstract:

Human pancreatic endocrine cells are proliferated without loss of hormone function in a culture medium containing extracellular matrix from bladder carcinoma cell lines in the substantial absence of hepatocyte growth factor/scatter factor. Proliferation is preferably carried out in the substantial absence of any peptide growth factors and nicotinamide. The cells may be proliferated in a monolayer on a solid substrate. Islets and islet-like cell clusters are proliferated without loss of insulin-secreting function by incubation in a medium containing extracellular matrix from a human bladder carcinoma cell line, preferably cell line ATCC HTB-9.

US Patent:

57233330, Mar 3, 1998

Filed:

Jul 31, 1995

Appl. No.:

8/509121

Inventors:

Fred Levine - Del Mar CA
Sijian Wang - San Diego CA
Gillian M. Beattie - Poway CA
Alberto Hayek - La Jolla CA

Assignee:

Regents of The University of California - Oakland CA

International Classification:

C12N 500
C12N 508
C12N 522
C12N 1563

US Classification:

435325

Abstract:

This invention relates to cell lines, particularly mammalian cell lines, established by transforming the cells with vectors, preferably retroviral vectors, containing two or more oncogenes under the control of one or more inducible promoters and/or genetic elements. Also within the scope of the invention are human cell lines with extended in vitro lifespan, transformed by vectors containing one or more oncogenes under the control of one or more, preferably exogenous, inducible promoters and/or genetic elements. The vectors may additionally contain gene(s) encoding for desired gene product(s). Also disclosed are insulin producing human pancreatic cell lines useful for transplantation into human diabetic patients.

US Patent:

51167530, May 26, 1992

Filed:

Jul 30, 1991

Appl. No.:

7/737758

Inventors:

Gillian M. Beattie - Poway CA
Douglas A. Lappi - Del Mar CA
J. Andrew Baird - San Diego CA
Alberto Hayek - La Jolla CA

Assignee:

The Salk Institute for Biological Studies - La Jolla CA
The Whittier Institute for Diabetes & Endocrinology - San Diego CA

International Classification:

C12N 506
C12N 508

US Classification:

4352402

Abstract:

The addition of basic FGF-saporin mitotoxins selectively elminates fibroblastoids from human islets in culture and increases the ability of such islets to release insulin under basal and stimulated conditions. When such islets are attached to an extracellular matrix, in particular BCEM, the proliferation of islet cells is favored, and the ability of islets cultured in such manner to release insulin is further increased. Moreover, supplementation of the culture media with high glucose or insulin further improves the functioning of the human islets, resulting in augmented insulin release. Combinations of such procedures offer a novel approach towards the establishment of viable human islet cell monolayers for clinical and laboratory research.